A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-05

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

NCT04234620

Melanoma Lung Cance Breast Cancer

UNKNOWN

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

NCT04472806

Mucosal Melanoma

UNKNOWN PHASE2

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

NCT04884997

Malignant Melanoma

UNKNOWN PHASE2

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

NCT05087602

Locally Advanced or Metastatic Acral Malignant Melanoma

UNKNOWN PHASE2

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

NCT03818893

Advanced Melanoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial includes two phases, Phase Ib and Phase II.

Phase Ib is an exploratory stage of safety and efficacy in a single-arm, open-label study, including three cohorts (different dosing regimens).Phase Ib includes three cohorts, Cohort 1 (LBL-024 monotherapy), Cohort 2 (LBL-024 + LBL-007 combination) and Cohort 3 (LBL-024 + toripalimab combination).

Phase II includes Part A and Part B.Part A is a randomized, open-label, positive-controlled extension study. It plans to enroll patients with melanoma of the cutaneous, Acral, and unknown primary. Eligible subjects will be randomly assigned in a 2:1 ratio \[Stratification factor: Acral subtype (Yes vs. No)\] to either the Experimental Group or the Control Group. Part B is a single-arm extension study enrolling only patients with mucosal melanoma,and will select a drug combination based on phase Ib efficacy for expansion study.

This study requires subjects to provide relevant samples for testing. The trial will enroll up to 200 subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LBL-024

Cohort 1 (LBL-024 monotherapy):

Subjects received treatment with LBL-024 , intravenous infusion.

Group Type EXPERIMENTAL

LBL-024 for Injection

Intervention Type DRUG

LBL-024 , Intravenous infusion.

LBL-024 + LBL-007 combination

Cohort 2 (LBL-024 + LBL-007 combination):

Subjects received treatment with LBL-024 combined with LBL-007 , intravenous infusion.

Group Type EXPERIMENTAL

LBL-024 for Injection

Intervention Type DRUG

LBL-024 , Intravenous infusion.

LBL-007 Injection

Intervention Type DRUG

LBL-007 , intravenous infusion.

LBL-024 + toripalimab combination

Cohort 3 (LBL-024 + toripalimab combination ):

Subjects received treatment with LBL-024 combined with toripalimab , both intravenous infusion.

Group Type EXPERIMENTAL

LBL-024 for Injection

Intervention Type DRUG

LBL-024 , Intravenous infusion.

Toripalimab Injection

Intervention Type DRUG

Toripalimab , intravenous infusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LBL-024 for Injection

LBL-024 , Intravenous infusion.

Intervention Type DRUG

LBL-007 Injection

LBL-007 , intravenous infusion.

Intervention Type DRUG

Toripalimab Injection

Toripalimab , intravenous infusion.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LBL-024 LBL-007 Toripalimab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
2. At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.
3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
4. The expected survival time is at least 12 weeks.
5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours）, the subjects enrolled have at least one measurable neoplasm lesion.
6. Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.

Exclusion Criteria

1. Subjects who received live vaccination within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose.
2. Major surgery or other treatment or diagnosis that has a significant impact on the subject within 4 weeks before the first dose.
3. Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.
4. History of severe cardiovascular and cerebrovascular disorder.
5. Active infectious disease.
6. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.
7. Women during pregnancy or lactation.
8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yu Chen

Role: PRINCIPAL_INVESTIGATOR

Fujian Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fujian Cancer Hospital

Fuzhou, Fujian, China

Site Status RECRUITING